Tertiary Hyperparathyroidism After Kidney Transplant: Cinacalcet or Parathyroidectomy
A single patient whose new kidney fixed one problem but not the one his parathyroid glands developed while waiting for it. The disagreement is whether medical therapy can still catch up, or whether the glands have become independent enough that only surgery will.
Anatoly S., a 48-year-old man, received a living-donor kidney transplant fourteen months ago after nearly six years on dialysis for CKD from IgA nephropathy — a wait he describes as the hardest stretch of his life, made bearable mostly by his teenage son, who is now the one nagging him to keep up with his follow-up labs. The transplant has functioned well from the start, with a creatinine that settled quickly to 1.1 and has stayed there.
What has not settled is his calcium: 11.1 on every check since transplant, alongside a PTH of 165 that is lower than his pre-transplant levels but inappropriately high against a kidney now working normally. His glands spent nearly six years under chronic stimulation before the transplant removed the stimulus, and the question is whether they have become genuinely autonomous or are still involuting — a process that takes the better part of a year in some patients and considerably longer, or never completes, in others. Cruzado and colleagues randomized this exact population, transplant recipients with persistent hypercalcemic hyperparathyroidism, to cinacalcet or subtotal parathyroidectomy, and surgery was superior on the primary endpoint of normalizing serum calcium. That is a real result about which intervention works better; it is not a result about which patients still need one. And what no test in his chart can currently supply is exactly that distinction. His sestamibi shows diffuse four-gland uptake rather than a single adenoma, which is consistent with autonomous hyperplasia and equally consistent with hyperplastic glands still involuting — the scan cannot separate the two, and neither can a calcium of 11.1 or a PTH of 165 read at a single point in time.
Whether the glands are still catching up or already independent
I'd try cinacalcet first, given how well his transplant is functioning. A meaningful proportion of post-transplant tertiary hyperparathyroidism patients achieve adequate calcium and PTH control on cinacalcet alone, without taking on parathyroidectomy's surgical risk or its own real risk of permanent hypoparathyroidism afterward.
Cruzado and colleagues randomized exactly this population — kidney-transplant recipients with persistent hypercalcemic hyperparathyroidism — to cinacalcet or subtotal parathyroidectomy, and surgery was superior on the primary endpoint of normalizing serum calcium. Fourteen months of persistent hypercalcemia, with a sestamibi scan showing diffuse four-gland uptake rather than a single adenoma, looks to me like glands that have become genuinely autonomous after years of secondary stimulation — no longer responding to the calcium feedback cinacalcet's mechanism depends on.
I take the surgical-risk concern seriously — I'm not dismissing it — I just think a medical trial in truly autonomous glands is more likely to be a delay than a genuine alternative, and that delay has its own cost.
I don't think fourteen months alone tells us which of you is right. Some patients' hyperplastic glands do involute gradually over the first year or more post-transplant — fourteen months sits in a genuinely ambiguous window where both autonomous and still-resolving glands remain plausible explanations for his numbers.
I'd propose a defined cinacalcet trial with explicit stop criteria — a specific calcium and PTH target by a set date — rather than either assuming it will work indefinitely or ruling it out before trying. If his glands are still involuting, this is exactly the window that would show it; if they're autonomous, the trial fails cleanly and surgery becomes the clear next step without having cost him more than a defined interval.
Agreed: a defined 12-week cinacalcet trial with explicit calcium and PTH targets set in advance, with parathyroidectomy planned directly if those targets aren't met, rather than an open-ended medical trial or immediate surgery.
Not fully settled: whether the four-gland diffuse uptake pattern on his sestamibi scan should shift the group's prior probability toward the surgeon's autonomous-gland read even before the trial concludes — raised but left as background context rather than a reason to shorten the agreed trial window.